Investigation and analysis of the clinical application of

Perampanel in the Southeast of China

Lingqi Li, Yan Huang*, Lei Ma, Zhiyu Shao

Lingqi Li : The pharmacy department of the First Affiliated Hospital of Xiamen University, Xiamen, 361102, China. Email: <u>527820802@qq.com</u> Yan Huang: The Department of Neurology of the First Affiliated Hospital of Xiamen University, Xiamen, 361102, China. Tel: 0086-0592-2137396 Fax: 0086-0592-2137396, Email: <u>ljj716@hotmail.com</u> Lei Ma: Department of Pharmacy, The First Affiliated Hospital of Xiamen University, Xiamen, 361005, China. Tel: 0086-0592-2137313 Email: 376641543@qq.com Zhiyu Shao: The pharmacy department of the First Affiliated Hospital of Xiamen

University, Xiamen, 361102, China. Tel: 0086-0592-2137396 Fax: 0086-0592-2137396, Email: <u>zhiyushao1963@qq.com</u>

ABSTRACT

Objective The aim of this study was to investigate the clinical trials of Perampanel (PER) at the First Affiliated Hospital of Xiamen University (FAHXU). Recommendations have been developed for the use of Perampanel in clinical practice.

Design A retrospective single-center validation study.

Setting A tertiary general hospital in Xiamen, a city located on the southeastern coast of China.

Participants A total of 831 prescriptions were included for 188 patients were treated with Perampanel.

Outcome measures Record the patient's medication, including the diagnosis of the patient's disease, the dose, course of medication, and the combination of medication, analyze the characteristics of the drug population and the medication unreasonableness by comparing the drug instructions and referring to relevant literature and guidelines.

Results PER was mainly used in Neurology. Epilepsy is the most common conditions prescribed. There were 119 cases of inconsistent drug indications, 56 inappropriate dosing frequency, 3 inconsistent dose, and 6 inconsistent dose adjustment intervals.

Conclusion There is an improper use of PER within the FAHXU. Greater attention should be paid to changes in patients' condition and observation of discomfort following medication administration. Monitoring of PER use should be further enhanced. A rational drug evaluation system should be established to promote the rational use of PER.

Article Summary

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Our study was one of the few studies on the clinical use of Perampanel, especially in Southeast China.

As a third-generation antiepileptic drug, data on the clinical rational drug use of Perampanel is limited in China.

There were several limitations worth noting. Firstly, the data in our study were collected at only one institution, thus not covering a broader population from other regions. Clinical outcomes, including medication efficacy and adverse events, were not tracked in patients with irrational medication use.

Strengths and limitations

Our study was one of the few studies on the clinical use of Perampanel, especially in Southeast China. As a third-generation antiepileptic drug, data on the clinical rational drug use of Perampanel is limited in China.

There were several limitations worth noting. Firstly, the data in our study were collected at only two institutions, thus not covering a broader population from other regions. Clinical outcomes, including medication efficacy and adverse events, were not tracked in patients with irrational medication use.

Abbreviations:

AED = antiepileptic drug; AL= alprazolam; Botox A = Botulinum toxin A; CBZ: Carbamazepine; CS = Corticosteroids; CZP = Clonazepam; DP = diazepam; FA= folic acid; LEV = Levetiracetam; LEXAPRO = Lexapro (Escitalopram); LTG = lamotrigine; OMP = Omeprazole; OXC = oxcarbazepine; PB = phenobarbital; PHB = Phenobarbital; PTA = Prednisone acetate; PPC = Polyene phosphatidylcholine; POT CL = potassium chloride; SV = sodium valproate; TPM = topiramate; ZBT = zolpidem;

Introduction

Epilepsy is a chronic, noncommunicable disorder of the brain characterized by transient central nervous system dysfunction¹. Seizure are defined as abnormal neuronal discharges in the brain². It has paroxysmal, transitory, repetitive, and stereotypic features^{3, 4}. The symptoms of epilepsy are usually body convulsions and tremors, with more severe episodes of momentary loss of consciousness or abnormal sensations lasting seconds to minutes⁵. The global incidence of epilepsy is approximately 50 per 10,000 people, with at least 50~70 million people are afflicted, indicating Epilepsy is one of the most common brain disorders ^{6, 7}. With 80% of epilepsy patients residing in developing countries⁸. The recurrence of seizures has a

serious impact on the patient's physical and mental health and impose a significant burden on the family and society⁹. The management of epilepsy is therefore an important and pressing clinical issue. In general, there are many methods to treat illness and relieve symptoms, including diet therapies, medication, surgery, psychotherapy and immunotherapy¹⁰. The main tool to control seizures is drugs¹¹.

Antiepileptic drugs (AEDs) can be roughly divided into three generations based on listing time. Valproic Acid, Ethyl Succinate, and Phenytoin are some of the first-generation AEDs. Oxcarbazepine, Levetiracetam and Topiramate are the second-generation AEDs. Lacamide, Isodoxorubicin Acetate and Perampanel represent the third generation of antiepileptic medications^{12, 13}. Perampanel (PER) (Fycompa[®]) is developed by the Japanese pharmaceutical company Eisai. As an new anti-epileptic drug, PER is a highly selective and non-competitive antagonist of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) glutamate receptors^{14, 15}.

PER, by targeting inhibition of postsynaptic AMPA receptors, induces an increase intracellular calcium ion, thus reducing neuronal excitability¹⁶. The mechanism of PER is distinct from that of other antiepileptic drugs, opening a new avenue for the treatment of epilepsy. PER was launched as a new antiepileptic drug in China in July 2021. As of January 2022, it is used at FAHXU. There are nearly 10 million patients with epilepsy in China, with approximately 400,000 new cases each year¹⁷. Relatively little evidence exists to guide PER use in China. The purpose of this article is to present an analysis of the unreasonable situation of PER in FAHXU in order to provide a reference for clinically irrational drug use, with the goal of promoting rational drug use, so that this drug can exert its best effect in the case of rational drug taking.

METHODS

Study design, data source and patient population

We used the Hospital Information System (HIS) at FAHXU, to collect PER prescription data from January 2022 to January 2023. FAHXU is a famous tertiary hospital in Southeast China, with 4,500 staffs, 2500 beds, and 5 million ambulatory care visits annually. It consists of 65 departments and treats patients of all ages. There were 100,000 visits to the neurology department each year. These data include patient department, basic physiologic information, drug use and dosage, medication duration, and concomitant medications. And compare the drug instructions, refer to relevant literature and guidelines, and analyze the rationality of the characteristics of the drug

users and the phenomenon of irrational drug use. In order to analyze the rationality of the PER use situation in FAHXU, we also compared the PER package insert.

RESULTS

From January 2022 to January 2023, PER was prescribed to a total of 188 patients in FAHXU, with a total of 831 prescriptions. Table 1 shows the basic characteristics of patients treated with PER, including gender, age and Body Mass Index (BMI).

Patients' basic situation	Copies	Proportion	Patients' basic situation	Copies	Proportion
Male	111	59.04%	< 12 years	6	3.19%
		40.96%			
Female	77		12 - 17 years	24	12.77%
BMI < 18	13	6.91%	18 - 39 years	100	53.19%
$18 \leq BMI < 24$	113	60.11%	40 - 59 years	50	26.60%
$BMI \geq 24$	62	32.98%	> 60 years	8	4.26%

Table 1 Demographic and clinical characteristics of epilepsy patients

Table 2 shows the distribution of services, and PER is primarily concentrated in the Neurology Outpatient Department, with a total of 724 prescriptions, accounting for 87.12% of cases.

Table 2 Distribution of Department and Diagnosis for the use of PER

Department	Copies	Proportion
Neurology clinic	724	87.12%
Epilepsy clinic	102	12.27%
Thoracic surgery outpatient I	2	0.24%
Pulmonary nodule specialist	1	0.12%
Neurosurgery clinic	1	0.12%
Pediatric Neurology Clinic	1	0.12%
Total	831	100%

Table 3 shows the diagnosis for the prescriptions, and it can be seen that the PER is primarily used for epilepsy, symptomatic epilepsy [secondary epilepsy], epileptic seizures, and other related disorders. More information about diagnosing PER can also be found in Table 3.

Disease diagnosis	Copies	Proportion
Epilepsy	555	66.79%
Symptomatic epilepsy [Secondary epilepsy]		11.91%
Symptomatic epilepsy	19	2.29%
Pain	15	1.81%
Intracranial space-occupying lesion (post glioma surgery)	11	1.32%
Post-traumatic syndrome, epilepsy	13	1.56%
Juvenile absence epilepsy	10	1.20%
Dizziness, headache syndrome, other specified	13	1.56%
Burn	9	1.08%
AVM embolization postoperative	8	0.96%
Encephalitis (Autoimmune encephalitis)	8	0.96%
Epilepsy (Psychomotor seizure)	6	0.72%
Seizures, intracranial parasitic infection (after surgery)	6	0.72%
Brain abscess (Postoperative)	6	0.72%
Sjögren 's Syndrome\[Sjogren' s]	6	0.72%
Limbic encephalitis (?)		0.60%
Observation of Suspected Diseases and Conditions		0.72%
Diffuse astroglioma WHO Grade II postoperative		0.36%
Lumbar disc herniation		0.36%
Epilepsy, mesial temporal lobe epilepsy with hippocampal		0.24%
sclerosis		
Antisynthetase syndrome	1	0.12%
Meningioma	1	0.12%
Partial seizures	1	0.12%
Frontal lobe epilepsy	1	0.12%
Anxiety state	1	0.12%
Immune-mediated encephalitis	1	0.12%
Hydrocephalus		0.12%
Postoperative chemotherapy for malignant tumor		0.12%
Sleep disorder	1	0.12%
Other (hepatitis B, sleep disorder, diabetes mellitus,		2.29%
bradycardia, chronic gastritis, methemoglobinemia)		
Total	831	100.00%

Table 3 Diagnosis of prescription diseases of PER tablets

Table 4 details the usage of PER within FAHXU (compared to the drug instructions). Overall, 119 prescriptions, 14.32%, were inconsistent with the indications for the PER; 56 prescriptions with inappropriate dosing frequency, representing 6.74%; three prescriptions with inconsistent dosage, 0.36% repentance, and six prescriptions had inappropriate dosage interval adjustments, 0.72%. More information on the use of the PER within FAHXU could be found in Table 4 as well.

	X	1 1 0	/
Type of use	Relevant manual content	Drug administration	Copies
Indications	Epilepsy in adults and children 12 years of age and older. Add-on therapy for partial seizures	Pain, Burn, Hepatitis B, Sleep disorder, Diabetes, Bradycardia, Chronic gastritis, Hemiglobin	119
Medication Route	Oral	None	0
Dose Frequency	Once daily	Twice daily	56
Administered Dosage	Adults and adolescents: (adjust dose range 2-12 mg according to disease)	1 mg	3
Adjust Dose Interval	Dose increases separated by at least 1 or 2 weeks	1 days, 3 days, 5 days	6
Target Population	Elderly: Use with caution	Use in Elderly 60 Years of Age	8
	Children < 12 years	Children < 12 years	6
Renal imp in patients impairm	pairment: Not recommended with moderate or severe renal ent or on hemodialysis	Moderate to severe renal impairment	6
Hepatic in moderate liv exceed 8 n patients wit	jury: Patients with mild and rer injury, the dose should not ng/day; No recommended in h severe liver dysfunction	None	0
Not recor	nmended during pregnancy	None	0
Not recon stopj if taking	nmended during lactation and ping Breast-feeding first medicine is necessary	None	0
Drug interactions	Oral Contraceptives	None	0
	Other Antiepileptic Drugs	OXC, PB, PER, SV, CBZ, LTG, TPM, LEV	557
	Cytochrome P450 Inducers	CS, PB, CBZ, OXC	179
	Cytochrome P450 Inhibitor	None	0
Other	Swallow whole, do not chew, crush or split.	1 mg, 3 mg, 5 mg	8

Table 4 Administration of PER Tablets (as compared to the package insert)

Note: OXC: oxcarbazepine; PB: phenobarbital; SV: sodium valproate;

CBZ: carbamazepine; LTG: lamotrigine; TPM: topiramate; LEV: levetiracetam; CS: Corticosteroids

Table 5 shows the combination use of PER in FAHXU hospital, with 311 prescriptions were combination with one antiepileptic drug, 231 prescriptions were in combination with two antiepileptic drugs, and 15 prescriptions were combination with three antiepileptic drugs.

Concomitant medication	Drug Name	Combined Antiepileptic Drug Varieties	Copies
Novel antiepileptic drug	LEV (378), SV (296), OXC (81), TPM (67), LTG (61)	Concomitant use of an antiepileptic drug	311
Traditional antiepileptic drugs	CBZ (32), PHB (25)	Combined with two antiepileptic drugs	231
Sedative hypnotic drugs	CZP (66), AL (6), ZBT (3), DP (1)	Combined with three antiepileptic drugs	15
Vitamins & Electrolytes	Vitamin B1 (125), POT CL (1), FA (1)		
Antidepressants	Duloxetine (12), Lexapro (9)		
Hormones	PTA (10)		
Gastrointestinal system medication	OMP (9)		
Hepatoprotective drugs	PPC (6)		
Antipsychotics	Olanzapine (6)		
Antimigraine drugs	Flunarizine (2)		
Central stimulant	Piracetam (4)		
Others	Botox A (5)		

Table 5 Concomitant medication of PER Tablets

Note: AL: alprazolam; CBZ: Carbamazepine; PHB: Phenobarbital; DP: diazepam; ZBT: zolpidem; CZP: Clonazepam; LEV: Levetiracetam; LTG: lamotrigine; FA: folic acid; POT CL: potassium chloride; Lexapro (Escitalopram); PTA: Prednisone acetate; OMP: Omeprazole; OXC: oxcarbazepine; PPC: Polyene phosphatidylcholine; SV: sodium valproate; TPM: topiramate; Botox A: Botulinum toxin A;

Discussion

Analysis of the Basic Characteristics of Patients Using PER

As shown in the table 1, 111 male patients, accounting for 59.04%, and 77 female patients, accounting for 40.96%, were treated with PER. This is consistent with fact that there are more males and fewer females with epilepsy in China. Patients under the age of 12 accounted for 3.19%, and according to the medication instructions, "the safety and efficacy of PER in children under 12 years old has not yet been established." The efficacy and safety of PER in 96 Chinese pediatric patients aged 2-14 years were reported by Qu and Chen, et al¹⁸. Treatment effect was good, safety was high and adherence was good. PER has been on the commercially available since 2008 and has been approved by the U.S. FDA in 2012 for the treatment of focal seizures in patients 12 years and older^{19, 20}, with progressively expanding indications in a variety of countries. PER is a new indication that was approved in China in July 2021, and can be used to treat patients with partial-onset seizures (with or without secondary generalized seizures) in adults and children aged 4 years and older²¹. Pending the author's investigation and analysis, the instructions have not been updated in time. Table 1 shows that, 32.98% of patients had a BMI \ge 24. Studies have shown that the use of antiepileptic drugs can cause weight gain. It is possible that the obese population in this study is related to PER use. Due to the short duration of clinical use of PER in China, there is a need to study the side effects leading to obesity.

Analysis of medication of PER in FAHXU hospital

Indications for PER

According to Table 3, PER is primarily used for the treatment of epilepsy, symptomatic epilepsy [secondary epilepsy], epileptiform convulsions and other diseases. Its indication is in accordance with the package insert. The indications include alternative diagnoses such as traumatic brain injuries and encephalitis, which are not included in the medication labeling, but these conditions may cause seizures. Traumatic brain injury (TBI) is a common cause of epilepsy, epidemiologic studies have demonstrated a clear relationship between the severity of injury and the likelihood of developing epilepsy ^{22, 23}. In addition, encephalitis, an inflammation and swelling of the brain, is a leading cause of acute symptomatic seizures and subsequent epilepsy, with approximately one-third of patients presenting with seizures^{24, 25}. Encephalitis may be of either infective or autoimmune in origin²⁶. We also included patients with intracranial

space-occupying lesions, seizure symptoms have been reported in 30-50% of patients with brain tumors, especially benign slow-growing brain tumors²⁷⁻²⁹. Even if the pain diagnosis does not match the routine use of antiepileptics, after the onset of disease, patients with epilepsy are subject to pain or headache³⁰⁻³². Studies have shown that during epileptic seizures, nerves in the brain are over discharged, leading to local tissue disruption, abnormal blood supply, and ultimately physical deterioration and death of some cells, resulting in the development of pain symptoms³³. The above analysis suggests that there is inappropriate prescriptions use of PER in FAHXU hospital. Consulting the cases reveals that most of them were seizures caused by other conditions, because physicians did not fully diagnose epilepsy, the indications were not suitable.

Frequency of dosing with PER

Table 4 shows the most common inappropriate dosing frequency is twice daily (56 cases, 6.74%). The pharmacokinetic studies of PER have shown that peak concentration is reached approximately one hour after oral administration, with an average half-life of 105 hours. The elimination half-lives after single and multiple doses are 52-129 hours and 66-90 hours, respectively. Steady-state blood concentrations are reached after 14 days of multiple doses. Pharmacokinetic characteristics are consistent with a singlecompartment model of first-order elimination. As a result, a once-daily dose is appropriate. PER is primarily used to treat epilepsy by suppressing abnormal nerve discharge in the brain. Seizures are most likely to occur while sleeping, when the inhibitory effect of the cerebral cortex is reduced, facilitating epileptic foci that have lost inhibition to produce abnormal discharges. Furthermore, neurons are also more likely to exhibit synchronized discharges, which can trigger epileptic seizures, during light sleep. Taking drugs at night can effectively control abnormal synchronized discharges of neurons, in addition to improving seizure status, alleviating the condition, and promoting early recovery from the disease. Therefore, it is recommended to take PER at night.

Concomitant use of PER.

Pharmacotherapy is the mainstay of treatment for epilepsy. Relevant guidelines suggest beginning with low-dose monotherapy. If monotherapy fails to control seizures or side effects occur, another type of monotherapy may be considered. PER has a different mechanism than other antiepileptic drugs. It is often treated as an adjunctive therapy to other antiepileptics. This survey shows that it is usually used in combination with other medications, with a total of 331 prescriptions for combination with one antiepileptic drug, 231 prescriptions for combination with two antiepileptic drugs, and 15 prescriptions for combination with three antiepileptic drugs. However, when used in combination with other antiepileptic drugs, attention should be given to drug-drug interactions. Antiepileptic drugs such as carbamazepine, phenytoin, and oxcarbazepine, which concomitantly take enzymatic inducers in the liver, have been shown to be effective, may enhance the rate of clearance of this product, leading to a reduction in the plasma concentration of PER¹⁴. Consequently, when combined with such antiepileptic drugs, attention must be paid to titrating the drug dosage to achieve efficacy.

Relatively high proportions of vitamin B1 is also prescribed, in addition to antiepileptic drugs. Vitamin B1 belong to the group of nutritional neurotrophic vitamins and have a certain effect of improvement in patients with epilepsy. They can stabilize the nerves and have a sedative effect. The combination of PER and VB1 can have a positive effect on the severity and frequency of seizures and on the side effects of the drugs on the body. It has been demonstrated by studies: Patients with epilepsy are often associated with the development of mental illness. ³⁴⁻³⁶. Depression is the most common mental illness in these patients, with an incidence as high as 30%, which is $5 \sim 20$ times that of the general population. Patients with epilepsy have a prognosis that is influenced by the comorbidity of mental illness, resulting in poor quality of life and early death³⁶⁻³⁹. Botulinum toxin type A, Botulinum Neurotoxin (BoNT) is also a drug combination. It inhibits acetylcholine release at axon terminals in surrounding neurons, paralyzes flaccid muscle, and reduces glandular secretions. BoNT has been empirically used in a wide variety of ophthalmological, gastrointestinal, urologic, orthopedic, dermatologic, secretory and pain disorders^{40, 41}. Research results show BoNT can inhibit neuronal excitability, reducing acute seizures as well as chronic spontaneous epileptic seizures. Thereby reducing neuronal damage and abnormal brain firing, providing a novel means of treating $epilepsy^{42-44}$.

Characteristics of PER

During this investigation, it was discovered that PER tablet had been ruptured and the drug dosage was 1 mg, 3 mg and 5 mg. The PER used in FAHXU is a scarless tablet made by Eisai Europe limited and is an unmarked tablet. It is clear from the instructions

that it should be swallowed whole and should not be chewed, crushed, or divided. PER tablet scission can lead to inaccurate dosing and debris creation. Although the loss of some debris may have little effect on the therapeutic effect in short term, antiepileptic drugs often require long-term use. Thus, drugs should be used in strict accordance with medication instructions.

Dose Adjustment Interval for PER

The study showed that some patients adjust the medication dosage within a range of 1 day to 16 weeks. The instruction of PER indicated that the dose should be adjusted at intervals of 2 weeks or at least one week. Studies have shown that the development of drug tolerance can be delayed by a reasonable interval between doses⁴⁵. Tolerance to antiepileptic drugs is an important cause of clinical treatment failure⁴⁶. Therefore, medication dosage adjustments should be made according to the drug instructions in a regular and reasonable manner, in order to slow down the development of drug tolerance.

Conclusions

In conclusion, epilepsy is a chronic neurologic disorder that severely affects patients' daily lives. Not only a medical problem, but also an important public health and social issue. Pharmacological is the most common method of treating epilepsy, and the clinical demand for antiepileptic drugs is increasing as a result of the long course of epilepsy and the prolonged duration treatment. The novel antiepileptic drug Perampanel offers a new option for the treatment of epilepsy. Irrational use of PER still occurs in FAHXU hospital. Changes in patients' illnesses and adverse event after medication should receive more attention. It is a need for an appropriate medication use assessment system to strengthen supervision of PER clinical use and promote rational medication use.

Acknowledgements The authors would like to acknowledge the assistance of staff at the Department of Information Technology at the hospital for data extraction.

Author Contributions LL and YH contributed to data collection, data analysis and writing of the article. ZS, LM gave advice on the design of the study. LL and YH helped collect data. All authors revised the manuscript and eventually approved it for publication. LL was responsible for the overall content as guarantor who accepted full responsibility for the finished work and the conduct of the study, had access to the data, and controlled the decision to publish.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and was approved by the Ethics Committee of the First Affiliated Hospital of Xiamen University.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

References

- 1 De Biase S, Gigli GL, Nilo A et al. Pharmacokinetic and pharmacodynamic considerations for the clinical efficacy of perampanel in focal onset seizures. *Expert Opinion on Drug Metabolism & Toxicology*. 2019; 15(2): 93-102.
- 2 Panayiotopoulos CP. In: C. P. Panayiotopoulos ed. A clinical guide to epileptic syndromes and their treatment. London: Springer London; 2010:21-63.
- 3 In: T. Moritani, S. Ekholm and P. L. Westesson eds. Diffusion-weighted mr imaging of the brain. Berlin, Heidelberg: Springer Berlin Heidelberg; 2005:95-106.
- 4 Rogawski MA. Revisiting ampa receptors as an antiepileptic drug target: Revisiting ampa receptors as an antiepileptic drug target. *Epilepsy Currents*. 2011; 11(2): 56-63.
- 5 Halabi NE, Daou RAZ, Achkar R et al. Comparative study for classification methods to predict and detect epilepsy seizure. Paper presented at 2020 IEEE 5th Middle East and Africa Conference on Biomedical Engineering (MECBME). Conference Year Conference 27-29 Oct. 2020s.
- 6 Song L, Liu F, Liu Y et al. Clonazepam add-on therapy for refractory epilepsy in adults and children. *Cochrane Database Syst Rev.* 2018; 5(5): CD012253.
- 7 Thijs RD, Surges R, O'Brien TJ et al. Epilepsy in adults. *Lancet.* 2019; 393(10172): 689-701.
- 8 Singh G and Sander JW. The global burden of epilepsy report: Implications for low- and middle-income countries. *Epilepsy & Behavior*. 2020; 105: 106949.
- 9 French JA and Gazzola DM. New generation antiepileptic drugs: What do they offer in terms of improved tolerability and safety? *Therapeutic Advances in Drug Safety*. 2011; 2(4): 141-58.
- 10 Felton EA and Cervenka MC. Dietary therapy is the best option for refractory nonsurgical epilepsy. *Epilepsia*. 2015; 56(9): 1325-29.
- 11 Liu G, Slater N and Perkins A. Epilepsy: Treatment options. *Am Fam Physician*. 2017; 96(2): 87-96.
- 12 Sankaraneni R and Lachhwani D. Antiepileptic drugs—a review. *Pediatric Annals.* 2015; 44(2): e36-e42.
- 13 Knezevic CE and Marzinke MA. Clinical use and monitoring of antiepileptic drugs. *The Journal of Applied Laboratory Medicine*. 2018; 3(1): 115-27.
- 14 Plosker GL. Perampanel. *CNS Drugs*. 2012; 26(12): 1085-96.

- 15 Steinhoff BJ. Introduction: Perampanel—new mode of action and new option for patients with epilepsy. *Epilepsia*. 2014; 55(s1): 1-2.
- 16 Lattanzi S and Striano P. The impact of perampanel and targeting ampa transmission on antiseizure drug discovery. *Expert Opinion on Drug Discovery*. 2019; 14(3): 195-97.
- 17 Lagrand T and Winogrodzka A. Late relapse myoclonus in a case of lance-adams syndrome. *BMJ Case Reports.* 2013; 2013: bcr2013201543.
- 18 Qu R, Dai Y, Chen X et al. Effectiveness and safety of perampanel in chinese paediatric patients (2-14 years) with refractory epilepsy: A retrospective, observational study. *Epileptic Disorders*. 2021; 23(6): 854-64.
- 19 Satlin A, Kramer LD and Laurenza A. Development of perampanel in epilepsy. *Acta Neurologica Scandinavica*. 2013; 127(s197): 3-8.
- 20 Frampton JE. Perampanel: A review in drug-resistant epilepsy. Drugs. 2015; 75(14): 1657-68.
- 21 Eisai Co. L. New drug approval for fycompa® for adjunctive treatment of partial onset seizures in china. <u>https://www.eisai.com/news/2019/news201978.html</u> (accessed 2020 July 9).
- 22 Lowenstein DH. Epilepsy after head injury: An overview. *Epilepsia*. 2009; 50(s2): 4-9.
- Annegers JF and Coan SP. The risks of epilepsy after traumatic brain injury. *Seizure*. 2000; 9(7): 453-57.
- 24 Yoshikawa T and Asano Y. Central nervous system complications in human herpesvirus-6 infection. *Brain and Development*. 2000; 22(5): 307-14.
- 25 Michael BD and Solomon T. Seizures and encephalitis: Clinical features, management, and potential pathophysiologic mechanisms. *Epilepsia*. 2012; 53(s4): 63-71.
- 26 Bauer J and Bien CG. Encephalitis and epilepsy. *Seminars in Immunopathology*. 2009; 31(4): 537-44.
- 27 Boon PA, Williamson PD, Fried I et al. Intracranial, intraaxial, space-occupying lesions in patients with intractable partial seizures: An anatomoclinical, neuropsychological, and surgical correlation. *Epilepsia*. 1991; 32(4): 467-76.
- 28 Villemure JG and de Tribolet N. Epilepsy in patients with central nervous system tumors. *Current Opinion in Neurology.* 1996; 9: 424–28.
- 29 Cascino GD. Epilepsy and brain tumors: Implications for treatment. *Epilepsia*. 1990; 31(s3): S37-S44.
- 30 Young GB and Blume WT. Painful epileptic seizures. *Brain*. 1983; 106(3): 537-54.
- 31 Headache classification committee of the international headache society (ihs) the international classification of headache disorders, 3rd edition. *Cephalalgia*. 2018; 38(1): 1-211.
- 32 Förderreuther S, Henkel A, Noachtar S et al. Headache associated with epileptic seizures: Epidemiology and clinical characteristics. *Headache: The Journal of Head and Face Pain.* 2002; 42(7): 649-55.
- 33 Hwang ST, Goodman T and Stevens SJ. Painful seizures: A review of epileptic ictal pain. *Current Pain and Headache Reports.* 2019; 23(11): 83.
- 34 Dodrill CB and Batzel LW. Interictal behavioral features of patients with epilepsy. *Epilepsia*. 1986; 27(s2): S64-S76.
- Goldstein MA and Harden CL. Epilepsy and anxiety. *Epilepsy & Behavior*. 2000; 1(4): 228-34.
- 36 Reynolds EH and Trimble MR. Epilepsy, psychiatry, and neurology. *Epilepsia*. 2009; 50(s3): 50-55.
- 37 Forthoffer N, Kleitz C, Bilger M et al. Depression could modulate neuropsychological status in epilepsy. *Revue Neurologique*. 2020; 176(6): 456-67.
- 38 García-Morales IMDP, de la Peña Mayor PMD and Kanner AMMD. Psychiatric comorbidities in epilepsy: Identification and treatment. *The Neurologist.* 2008; 14(6).
- Hermann BP, Struck AF, Busch RM et al. Neurobehavioural comorbidities of epilepsy: Towards a network-based precision taxonomy. *Nature Reviews Neurology*. 2021; 17(12): 731-46.
- 40 Chen S. Toxins. 2012:913-39.
- 41 Pirazzini M, Rossetto O, Eleopra R et al. Botulinum neurotoxins: Biology, pharmacology, and toxicology. *Pharmacological Reviews*. 2017; 69(2): 200.
- 42 Peng Chen Z, Morris JG, Rodriguez RL et al. Toxins. 2012:1196-222.
- 43 Caleo M and Restani L. Toxins. 2018.
- 44 Bozzi Y, Costantin L, Antonucci F et al. Action of botulinum neurotoxins in the central nervous system: Antiepileptic effects. *Neurotoxicity Research*. 2006; 9(2): 197-203.
- 45 Eadie MJ. Shortcomings in the current treatment of epilepsy. *Expert Review of Neurotherapeutics.* 2012; 12(12): 1419-27.

46 Sisodiya SM, Lin WR, Harding BN et al. Drug resistance in epilepsy: Expression of drug resistance proteins in common causes of refractory epilepsy. *Brain*. 2002; 125(1): 22-31.